Rozalyn Levine Rodwin, MD
Assistant ProfessorCards
About
Research
Publications
2024
Patterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic
Kang L, Kadan-Lottick N, Rotatori J, Kujawski S, Messerschmidt E, Auerbach C, Balsamo L, Lustberg M, Ma X, Rodwin R. Patterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic. Seminars In Oncology Nursing 2024, 151716. PMID: 39164160, DOI: 10.1016/j.soncn.2024.151716.Peer-Reviewed Original ResearchChildhood cancer survivorsChemotherapy-induced peripheral neuropathyCharacteristics of survivorsPhysical therapyPercentage of adultsPT referralSurvivorship clinicCancer survivorsAttended PTPT attendanceNeighborhood characteristicsChemotherapy-induced peripheral neuropathy symptomsCancer survivorship clinicPhysical therapy referralsHigh school diplomaSurvivor educationCare coordinationOlder survivorsTherapy referralsImprove attendanceMedian percentageCancer diagnosisSchool diplomaPercentage of householdsAttendanceMotor and sensory impairment in survivors of childhood central nervous system (CNS) tumors in the St. Jude Lifetime Cohort (SJLIFE)
Rodwin R, Wang F, Lu L, Li Z, Srivastava D, Phillips N, Khan R, Brinkman T, Krull K, Boop F, Armstrong G, Merchant T, Gajjar A, Robison L, Hudson M, Kadan‐Lottick N, Ness K. Motor and sensory impairment in survivors of childhood central nervous system (CNS) tumors in the St. Jude Lifetime Cohort (SJLIFE). Cancer Medicine 2024, 13: e7422. PMID: 39056576, PMCID: PMC11273544, DOI: 10.1002/cam4.7422.Peer-Reviewed Original ResearchConceptsSt. Jude Lifetime CohortQuality of lifeChildhood central nervous systemSurvivors of childhood CNS tumorsSensory impairmentChildhood CNS tumorsImpaired physical quality of lifeCentral nervous systemPhysical quality of lifeMotor impairmentCNS tumorsCommon Terminology Criteria for Adverse EventsModified total neuropathy scoreMultivariate modelIn-person evaluationAssociated with older ageClinical assessmentTotal Neuropathy ScoreNervous systemExposure to etoposideModified Common Terminology Criteria for Adverse EventsPrevalence of motorTreating motor impairmentIn-personCraniospinal irradiation
2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkersHispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study
Graham C, Metayer C, Morimoto LM, Wiemels JL, Siddique A, Di M, Rodwin RL, Kadan-Lottick NS, Ma X, Wang R. Hispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 1788-1795. PMID: 35709749, PMCID: PMC9444874, DOI: 10.1158/1055-9965.epi-22-0335.Peer-Reviewed Original ResearchConceptsNon-Hispanic whitesHodgkin's lymphomaCase-control studyBirth characteristicsMaternal birthplaceMaternal agePopulation-based case-control studyMultivariable logistic regression modelConfidence intervalsEthnic differencesEarly-onset cancersPotential ethnic differencesForeign-born mothersLogistic regression modelsEthnicity differencesRace/ethnicityYear of birthLymphomaPaternal ageFemale HispanicsHispanic casesMale HispanicsHodgkinAgeRiskPersistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia
Rodwin RL, Kairalla JA, Hibbitts E, Devidas M, Whitley MK, Mohrmann CE, Schore RJ, Raetz E, Winick NJ, Hunger SP, Loh ML, Hockenberry MJ, Angiolillo AL, Ness KK, Kadan-Lottick NS. Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. Journal Of The National Cancer Institute 2022, 114: 1167-1175. PMID: 35552709, PMCID: PMC9360458, DOI: 10.1093/jnci/djac095.Peer-Reviewed Original ResearchPhysical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia
Rodwin RL, Ma X, Ness KK, Kadan-Lottick NS, Wang R. Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia. JCO Oncology Practice 2022, 18: e1060-e1068. PMID: 35427182, PMCID: PMC9287366, DOI: 10.1200/op.21.00796.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaPediatric acute lymphoblastic leukemiaPhysical therapyPhysical functionLymphoblastic leukemiaNeuromuscular conditionsImpaired physical functionPhysical therapy utilizationPremier Healthcare DatabasePediatric hematologists/oncologistsEarly physical therapyInpatient physical therapyHematologists/oncologistsLong-term healthCohort studyFirst hospitalizationMultivariable analysisTherapy utilizationClinical variablesTeaching hospitalHealthcare databasesPatientsAddress disparitiesHospitalAge 10Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions
Rodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. Frontiers In Pain Research 2022, 3: 864910. PMID: 35360655, PMCID: PMC8963873, DOI: 10.3389/fpain.2022.864910.Peer-Reviewed Original ResearchPeripheral neuropathyChemotherapy-Induced Peripheral NeuropathyTreatment of CIPNMultiple chemotherapeutic agentsQuality of lifeImportant clinical toolCancer survivorsTherapeutic optionsCIPNClinical practicePreventative treatmentPromising biomarkerChemotherapeutic agentsClinical implicationsClinical toolCancer diagnosisBiomarkersNeuropathyStandardized objective measuresPatientsObjective measuresTreatmentRiskChemotherapyComplicationsPatient-reported neurocognitive function in adult survivors of childhood and adolescent osteosarcoma and Ewing sarcoma
Kadan-Lottick NS, Zheng DJ, Wang M, Bishop MW, Srivastava DK, Ross WL, Rodwin RL, Ness KK, Gibson TM, Spunt SL, Okcu MF, Leisenring WM, Robison LL, Armstrong GT, Krull KR. Patient-reported neurocognitive function in adult survivors of childhood and adolescent osteosarcoma and Ewing sarcoma. Journal Of Cancer Survivorship 2022, 17: 1238-1250. PMID: 35059962, PMCID: PMC9300774, DOI: 10.1007/s11764-021-01154-z.Peer-Reviewed Original ResearchConceptsChronic health conditionsLong-term neurocognitive outcomesNeurocognitive outcomesNeurocognitive difficultiesChildhood osteosarcomaHealth conditionsChildhood Cancer Survivor Study Neurocognitive QuestionnaireAdult survivorsModified Poisson regressionPotential risk factorsOsteosarcoma survivorsSarcoma survivorsNeurocognitive QuestionnaireRisk factorsHigh prevalenceEwing's sarcomaPatient reportsNeurological conditionsRespiratory conditionsTreatment exposureNeurocognitive functionPoisson regressionOsteosarcomaDiagnostic groupsComorbid impairments
2021
Newly identified chemotherapy‐induced peripheral neuropathy in a childhood cancer survivorship clinic
Rodwin RL, Ross WL, Rotatori J, Allen K, Auerbach C, Balsamo LM, Kadan‐Lottick N. Newly identified chemotherapy‐induced peripheral neuropathy in a childhood cancer survivorship clinic. Pediatric Blood & Cancer 2021, 69: e29550. PMID: 34971076, PMCID: PMC8805800, DOI: 10.1002/pbc.29550.Peer-Reviewed Original ResearchClinical decision rule for obtaining peripheral blood cultures in febrile oncology patients
Gorfinkel L, Hansen CE, Teng W, Shabanova V, Prozora S, Rodwin R, Qadri U, Manghi T, Emerson B, Riera A. Clinical decision rule for obtaining peripheral blood cultures in febrile oncology patients. Pediatric Blood & Cancer 2021, 69: e29519. PMID: 34939321, DOI: 10.1002/pbc.29519.Peer-Reviewed Original ResearchConceptsPediatric emergency departmentPeripheral blood culturesPediatric oncology patientsFebrile oncology patientsClinical decision ruleOncology patientsBlood culturesBloodstream infectionsPositive peripheral blood cultureDiagnostic prediction toolsInternal validationRetrospective chart reviewAcute myeloid leukemia diagnosisRecent systematic reviewClinical prediction modelReceiver operator curveVasopressor supportActive therapyChart reviewDerivation cohortIndependent predictorsEmergency departmentPatientsSystematic reviewOperator curve
Clinical Trials
Current Trials
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
HIC ID2000032978RoleSub InvestigatorPrimary Completion Date12/30/2026Recruiting ParticipantsA Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease
HIC ID2000032707RoleSub InvestigatorPrimary Completion Date08/01/2025Recruiting ParticipantsA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)
HIC ID2000032969RoleSub InvestigatorPrimary Completion Date07/05/2028Recruiting ParticipantsA Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
HIC ID2000028691RoleSub InvestigatorPrimary Completion Date05/01/2027Recruiting ParticipantsA Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
HIC ID2000028692RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting Participants
Clinical Care
Overview
Clinical Specialties
Pediatric Hematology & Oncology
Fact Sheets
Acute Lymphoblastic Leukemia (ALL)
Learn More on Yale MedicineNeutropenia
Learn More on Yale MedicineLeukemia in Children
Learn More on Yale MedicineCytogenic Studies for Leukemia Diagnosis
Learn More on Yale Medicine
Yale Medicine News
News
News
- September 25, 2023
Rozalyn Rodwin, MD, in honor of Childhood Cancer Awareness Month
- August 17, 2023
Rozalyn Levine Rodwin, MD, Awarded $100,000 Grant to Treat Survivors of Childhood Cancer
- August 16, 2023Source: WTNH
Yale New Haven Children’s Hospital gets $100K grant
- June 09, 2021
Yale Cancer Center Study Shows Neuromuscular Dysfunction in Long-term Childhood Cancer Survivors